AnalystScope equity researchCurrent company view

DHR

Danaher Corporation

Health Care / Life Sciences Tools & Services / Washington, DC

View printable snapshot

AnalystScope signal

Buy

Scheduled quote

$195

Base fair value

$268

Bear / base / bull

$205 / $268 / $304

Upside / downside

+37.4 upside

Confidence

Medium

Research updated Jun 13, 2026

Daily scheduled refresh as of Aug 1, 2026, 6:05 AM UTC. Fresh through Aug 2, 2026, 6:05 AM UTC.

Informational research only. Not personalized investment advice.

Model vs published view

Current model signal differs from the latest published analyst rating.

Live current-price moves may be widening the gap versus the latest published view.

Investment summary

Current view and thesis

Danaher Corporation is added as a high-quality large-cap coverage candidate with life sciences and diagnostics tools portfolio with process-driven operating discipline. The initial AnalystScope view weighs bioprocessing recovery, diagnostics durability, and portfolio execution against quality multiple requires clearer bioprocessing recovery evidence, keeping the rating restrained until the model has more live refresh history.

Fair value $268 vs. current $195 (+37.4 upside). Current base fair value is $268 versus $195, implying +37.4 upside.

Key drivers

Bioprocessing recovery can support growth.

Operating discipline improves margin resilience.

Portfolio quality supports cash conversion.

Key risks

Bioprocessing demand may recover slower than expected.

Acquisition execution and leverage can affect returns.

Diagnostics normalization can pressure growth.

What would change the view

A clearer evidence base around bioprocessing recovery, diagnostics durability, and portfolio execution would improve confidence.

A deterioration in danaher operating discipline supports strong margins and cash conversion would reduce support for the current fair value.

A wider gap between price and normalized cash-flow support would make the rating harder to defend.

Valuation

Price, range, and method support

Base case $268 / +37.4 upside / medium confidence

Price vs fair value

+37.4%

Model-implied return

Scheduled quote

$195

Fair value

$268

Valuation method stack

Weighted fair value $268

Published method weights

DCF (Base)

$274 | 45%

NTM P/E Multiple

$265 | 35%

EV/EBITDA Cross-check

$260 | 20%

Case / method	Value	Weight / support
DCF (Base)	$274	45%
NTM P/E Multiple	$265	35%
EV/EBITDA Cross-check	$260	20%
Bear case	$205	Mixed
Base case	$268	Mixed
Bull case	$304	Mixed

Fundamental analysis

Reported evidence and normalized model base

Normalized annual basis: FY2025

Download reported financials CSV Download normalized financials CSV

Normalized figures are AnalystScope's annual valuation model base.

Normalized metric	Latest value	Growth / margin context
Revenue	$25.8B	+5.3% YoY
Operating income	$6.5B	25.2% margin
Net income	$4.9B	EPS proxy $6.65
Free cash flow	$6.6B	25.6% margin
EBITDA	$8.2B	31.8% margin
Net cash / (debt)	-$14.0B	-54.3% of revenue

Metric	Reported	AnalystScope normalized	Basis note
Revenue (TTM)	$24.6B	$25.8B	Model revenue smooths short-term demand, timing, and segment-mix volatility rather than treating the latest period as a straight-line run rate.
Operating Margin	19.1%	25.2%	Margin input uses a durable operating base and tempers one-off restructuring, mix, and cycle effects.
FCF (TTM)	$5.3B	$6.6B	FCF input normalizes working-capital and capital-spending timing so cash conversion is not over-read from one period.
Net Cash / (Debt)	($20.8B)	($14.0B)	Balance-sheet input uses a conservative net cash / debt posture without assuming all cash is excess or fully distributable.

Fundamental snapshot

FY2025

Normalized annual model base

Revenue

+5.3% YoY

$25.8B

Op. margin

+0.7% pts

25.2%

FCF margin

+1.1% pts

25.6%

Revenue + margin trend

Annual normalized model-base history.

Revenue

2023

2024

2025

Operating margin

2023

2024

2025

AnalystScope annual model-base statements in USD across FY2023 | FY2024 | FY2025.

Income statement

Line item	FY2023	FY2024	FY2025
Revenue	$23.9B	$24.5B	$25.8B
Gross Profit	$14.1B	$14.6B	$15.5B
Operating Income	$5.7B	$6.0B	$6.5B
EBITDA	$7.3B	$7.6B	$8.2B
Net Income	$4.3B	$4.5B	$4.9B

Balance sheet

Line item	FY2023	FY2024	FY2025
Cash & Investments	$6.5B	$7.0B	$7.5B
Total Debt	$21.0B	$21.2B	$21.5B
Net Cash / (Debt)	($14.5B)	($14.2B)	($14.0B)
Total Assets	$84.0B	$86.0B	$88.0B
Total Liabilities	$37.0B	$37.0B	$37.0B
Shareholders' Equity	$47.0B	$49.0B	$51.0B

Cash flow

Line item	FY2023	FY2024	FY2025
Operating Cash Flow	$6.5B	$6.9B	$7.5B
Depreciation & Amortization	$1.6B	$1.6B	$1.7B
Capital Expenditures	($800.0M)	($900.0M)	($900.0M)
Free Cash Flow	$5.7B	$6.0B	$6.6B

Model assumptions

Base-case inputs and sensitivity

Published AnalystScope assumptions; private edits do not change this base case.

Revenue CAGR (5Y)

5.0%

+/- 1.0% => +/-$7/sh

Why this level: This is AnalystScope's base-case growth assumption, not a guarantee. It sits below the latest FY model-base revenue pace (2025.0%), so the model does not extend current strength too far into the outer years. Current company context: Bioprocessing recovery can support growth.

Terminal Growth

2.5%

+/- 0.5% => +/-$6/sh

Why this level: This is AnalystScope's mature long-run growth assumption, not a perpetual hypergrowth claim. At 2.5%, it sits well below the 5.0% five-year revenue CAGR, so the model steps down from the explicit forecast period to a steadier long-run pace. For Danaher Corporation, that means a durable franchise can keep compounding after year five without assuming today's faster growth profile lasts indefinitely.

WACC

8.1%

+/- 0.5% => -$10/sh

Why this level: This is AnalystScope's base-case cost-of-capital judgment, not a precise CAPM output. It reflects the current rates backdrop, equity risk premium, and the company's balance-sheet posture. Debt is manageable but demand recovery remains important

Operating Margin (Year 5)

26.0%

+/- 100 bps => +/-$6/sh

Why this level: This is AnalystScope's base-case margin view, not a promise of straight-line expansion. It keeps year-five margins close to today's model-base operating margin (25.2%), which implies the current margin structure is broadly durable. Margin input uses a durable operating base and tempers one-off restructuring, mix, and cycle effects.

Sensitivity drivers

Revenue CAGR (5Y)

5.0%

+/- 1.0% => +/-$7/sh

Terminal Growth

2.5%

+/- 0.5% => +/-$6/sh

WACC

8.1%

+/- 0.5% => -$10/sh

Operating Margin (Year 5)

26.0%

+/- 100 bps => +/-$6/sh

Confidence

Medium

Method outputs are tightly grouped at +5.2% dispersion.

Why the model view could be wrong

Bioprocessing demand may recover slower than expected.

Acquisition execution and leverage can affect returns.

Diagnostics normalization can pressure growth.

Private analysis

Test your own assumptions in Scenario Builder

Private scenarios remain separate from AnalystScope's published base case.

Open Scenario Builder

Private workspace

Scenario Builder

Private scenario sandbox

This is a private modelling layer, not the public AnalystScope base case or printable snapshot. It keeps the public base case as the anchor, applies bounded changes to the four core valuation inputs, and updates your scenario fair-value estimate immediately.

Saved scenarios currently stay local to this browser for DHR. Base-case rationale remains in the public assumptions section above. Your scenario output reprices the published valuation methods from projected operating anchors when those anchors are available, while keeping market-multiple and capital-structure assumptions anchored to the AnalystScope framework.

Editable assumptions

Adjust your scenario inputs within the displayed plausible range for this company. The workbench stays anchored to the public AnalystScope base case.

This is a bounded scenario tool, not a free-form spreadsheet. Values outside the displayed range snap back to the nearest allowed value when you leave the field.

Matches the published AnalystScope base case.

Revenue CAGR (5Y)

Public AnalystScope base case: 5.0% | +/- 1.0% => +/-$7/sh

Allowed range: 0.0% to 11.0%

Terminal Growth

Public AnalystScope base case: 2.5% | +/- 0.5% => +/-$6/sh

Allowed range: 1.0% to 4.0%

WACC

Public AnalystScope base case: 8.1% | +/- 0.5% => -$10/sh

Allowed range: 6.1% to 10.1%

Operating Margin (Year 5)

Public AnalystScope base case: 26.0% | +/- 100 bps => +/-$6/sh

Allowed range: 18.0% to 34.0%

Saved private scenarios

Save up to 5 named scenarios for DHR. These are your scenarios: they never overwrite the public AnalystScope base case and remain clearly separate from public research.

Browser-local workspace0 / 5 saved

Checking private workspace session...

Private scenario note

Keep a short thesis, main risk, or why this case differs from the published base case.

0 / 280

Notes stay local to this browser unless you sign in to the private workspace, and they never appear as published AnalystScope research.

No private scenarios saved yet. Make a change to the published base case, then save a named scenario here.

Published base case

Fair value

$268

Upside / Downside

+37.4 upside

Model signal

Buy

Published base-case output

Scenario output reprices the published DCF and multiple methods from projected year-5 revenue, margin, free cash flow, EBITDA, and EPS anchors. Market multiples and capital structure stay anchored to the published base framework.

Fair value

$268

$0/sh vs published base case

Upside / Downside

+37.4 upside

+0.0 pts vs published base case

Model signal

Buy

Unchanged versus the published base case.

Method movement inside the scenario

This breakdown shows what moved inside the published valuation framework when you edit the scenario. The published AnalystScope base case stays anchored, and any method without a clean projected anchor remains pinned to that framework.

Method rows below reflect the current edited scenario state, not just the saved scenario snapshots.

Influence tags are directional rather than exact attribution. They estimate which edited input is moving each method most by reverting one assumption at a time while the other edited inputs stay in place.

3 of 3 methods support model-native repricingModel-native bridge

Method	Published base	Edited scenario	Delta	How it moved / main drivers
DCF (Base) DCF-style \| 45% weight	$274	$274	$0/sh	Base-aligned This method is supported by the model-native bridge and currently stays aligned with the published base case. Edited inputs are largely offsetting each other, so this row stays close to the published base case.
NTM P/E Multiple P/E-style \| 35% weight	$265	$265	$0/sh	Base-aligned This method is supported by the model-native bridge and currently stays aligned with the published base case. Edited inputs are largely offsetting each other, so this row stays close to the published base case.
EV/EBITDA Cross-check EV-based multiple \| 20% weight	$260	$260	$0/sh	Base-aligned This method is supported by the model-native bridge and currently stays aligned with the published base case. Edited inputs are largely offsetting each other, so this row stays close to the published base case.
Weighted fair value Published framework result \| Published framework result	$268	$268	+$0/sh	Moved Combines the repriced method outputs using the published AnalystScope weights. No single edited assumption is dominating this move in a material way.

Published base case vs private scenarios

Compare the published AnalystScope base case against your saved private scenarios in one view. Saved scenarios remain local to this browser, and the table below reflects saved snapshots rather than any unsaved edits currently sitting in the editor.

Fair-value comparisons use the same workbench recalculation path as the editor above.

Published base case stays pinned as the anchor row.

Scenario	Revenue CAGR (5Y)	Terminal Growth	WACC	Op. Margin (Y5)	Fair Value	Upside / Downside	Model Signal	Delta vs Base	Action
AnalystScope base case Published Official AnalystScope anchor row.	5.0%	2.5%	8.1%	26.0%	$268	+37.4 upside	Buy	Published anchor

Supporting research

Quality, normalization, and monitoring evidence

Annual model base: FY2023 | FY2024 | FY2025

Thesis scorecard

Growth

Moderate

bioprocessing recovery, diagnostics durability, and portfolio execution

Profitability

Strong

Danaher operating discipline supports strong margins and cash conversion

Balance sheet

Moderate

debt is manageable but acquisition strategy keeps leverage relevant

Valuation

Moderate

quality multiple requires clearer bioprocessing recovery evidence

Execution / Resilience

Moderate

end-market recovery timing and portfolio execution are the main risks

Current source status

Quote: Daily scheduled refresh as of Aug 1, 2026, 6:05 AM UTC. Fresh through Aug 2, 2026, 6:05 AM UTC.

Reported fundamentals: Fundamentals refreshed 1 Aug 2026, 16:00 UTC. Fresh through 2 Aug 2026, 04:00 UTC.

Latest filing: 8-K filed Jul 21, 2026 | Reporting period Jul 21, 2026. Filing refreshed Aug 1, 2026, 4:00 PM UTC. Fresh through Aug 2, 2026, 4:00 AM UTC.

Annual model-base income-statement, cash-flow, and balance-sheet metrics, plus cross-statement quality relationships with compact prior-FY direction cues, derived from the curated statement backbone.

Basis: FY2023 | FY2024 | FY2025. Live reported fundamentals remain available in the reconciliation section.

Operating and cash-flow trends

Model-base statements

Revenue growth (1Y)

+5.3%

Gross margin

60.1%

Operating margin

25.2%

Operating margin change vs prior FY

+0.7 pts

EBITDA margin

31.8%

EBITDA margin change vs prior FY

+0.8 pts

Operating income growth (1Y)

+8.3%

Net margin

19.0%

FCF margin

25.6%

FCF margin change vs prior FY

+1.1 pts

FCF growth (1Y)

+10.0%

Balance sheet quality

Model-base statements

Cash & investments

$7.5B

Total debt

$21.5B

Net cash / (debt)

Net debt $14.0B

Net cash / (debt) as % of revenue

Net debt 54.3% of revenue

Liabilities / assets

Stable

vs FY2024 (-1.0 pts)

42.0%

Cross-statement quality

Model-base statements

Gross-to-operating spread

34.9 pts

Operating cash flow / net income

Stable

vs FY2024 (-0.0x)

1.5x

Operating cash flow / EBITDA

Stable

vs FY2024 (+0.0x)

0.9x

Free cash flow / net income

Stable

vs FY2024 (+0.0x)

1.3x

CapEx as % of revenue

Stable

vs FY2024 (-0.2 pts)

3.5%

CapEx as % of operating cash flow

Stable

vs FY2024 (-1.0 pts)

12.0%

CapEx / D&A

Stable

vs FY2024 (-0.0x)

0.5x

Cash & investments / total debt

Stable

vs FY2024 (+0.0x)

0.3x

Shareholders' equity as % of revenue

197.7%

Asset turnover

Stable

vs FY2024 (+0.0x)

0.3x

Compact model-base diagnostics for analyst triage, highlighting where the durable valuation base is diverging most clearly from the latest reported picture.

Adjustment focus

Large analyst adjustment

Balance sheet | Net Cash / (Debt) | +$6.8B / +28% of revenue

Revenue momentum

Stable

+5.3% latest 1Y growth

vs +2.5% prior 1Y

Operating margin trend

Stable

25.2% latest margin

+70 bps vs prior FY

FCF margin trend

Improving

25.6% latest FCF margin

+109 bps vs prior FY

Balance-sheet posture

Strengthening

Net debt 54.3% of revenue

vs Net debt 58.0% of revenue prior FY

How to read this

Reported = the latest company-reported figure. Model base = AnalystScope's comparable operating base used for valuation and thesis work. It may include standardization, conservative balance-sheet treatment, working-capital cleanup, and through-cycle adjustments when current reported numbers do not look durable.

This is an analyst model base, not a claim of perfect adjusted truth. Larger gaps can reflect deliberate cyclical or base-case adjustments, not just light accounting cleanup.

Why the model base differs

This initial coverage setup keeps valuation tied to durable normalized fundamentals and avoids letting a single recent print dominate the public view.

Rows are sorted by largest comparable adjustment first.

Metric	Model base	Live reported	Variance vs reported	Adjustment size	Why lower / higher?
Net Cash / (Debt)	($14.0B) FY2025 model base	($20.8B) Live reported balance sheet	+$6.8B / +28% of revenue	Large analyst adjustment	Model base is less conservative than the live reported balance-sheet figure because the latest reported balance does not appear fully representative. It balance-sheet input uses a conservative net cash / debt posture without assuming all cash is excess or fully distributable.
FCF (TTM)	$6.6B FY2025 model base	$5.3B Live reported TTM	+$1.3B / +25%	Large analyst adjustment	Model base is higher than live reported because the model does not assume the latest cash-flow drag is fully durable. It normalizes working-capital and capital-spending timing so cash conversion is not over-read from one period.
Operating Margin	25.2% FY2025 model base	19.1% Live reported margin	+6.1 pts	Large analyst adjustment	Model base is higher than live reported because the model does not assume the latest reported margin pressure is the durable earnings base. It uses a durable operating base and tempers one-off restructuring, mix, and cycle effects.
Revenue (TTM)	$25.8B FY2025 model base	$24.6B Live reported TTM	+$1.2B / +5%	Close to reported	Model base is higher than live reported because the thesis does not assume the latest reported softness is the durable revenue run-rate. It smooths short-term demand, timing, and segment-mix volatility rather than treating the latest period as a straight-line run rate.

Near-term catalysts

Next quarterly update and management commentary on demand quality.

Reported margin, cash-flow conversion, and balance-sheet movement versus the normalized model base.

Daily scheduled quote refreshes that tighten the current price-versus-fair-value read.

What we are watching

Bioprocessing order trends.

Core margin progression.

Cash conversion and acquisition discipline.

Date	Event	Published rating	Note
Jun 13, 2026	New	Hold	Started coverage with a Hold view on quality tools exposure versus recovery timing.